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INTRODUCTION
The kinetics of plasma very low density lipoprotein (VLDL)l and low density lipoprotein (LDL) metabolism in man have been the subject of numerous investigations. It is now established that a precursorproduct relationship exists between VLDL-apolipoprotein B (apo B) and LDL-apo B, and that lipoproteins of intermediate density and flotation rate are intermediate in this metabolic sequence (1) (2) (3) (4) . Normally, all LDLapo B is derived from VLDL-apo B (2) (3) (4) , but in familial hypercholesterolemia there is evidence of LDL-apo B synthesis not involving VLDL as a precursor, in both the homozygous (5) and heterozygous (6) forms. Oversecretion of VLDL-apo B has been reported in hypertriglyceridemia (3, 7, 8) , particularly in hypertriglyceridemia due to familial combined hyperlipidemia (9) . Catabolic defects may underlie other disorders characterized by elevated plasma triglyceride levels (4, 5, 7, 10) .
Most studies have used preparations of autologous VLDL, LDL and/or intermediate lipoprotein classes or Sf 12-60) labeled in vitro with radioiodine. After intravenous injection of such radiolabeled lipo-proteins, sequential peripheral blood samples have been assayed for apo B specific activity in different lipoprotein fractions, and the specific activity time curves analyzed to give values for the pool sizes, production rates, interconversion and fractional rates ofcatabolism of the lipoproteins. Other procedures to label apo B have also been used (11) . The use of apo B as a marker of the metabolism of these lipoproteins appears to be particularly apt, as this protein is quantitatively conserved during the metabolism ofVLDL and LDL, playing a structural role in the composition of the particles (1, 4, 12) .
Possible discrepancies exist between certain of the published accounts ofVLDL-apo B metabolism in man. Though the transfer of apo B from larger to smaller VLDL subclasses appears to be quantitative in normolipidemic subjects, it is unclear whether all apo B is transferred to LDL. Sigurdsson et al. (2) concluded that more than 90% of VLDL-apo B is normally transferred to the Sf 0-20 range (2) , and other studies have suggested that most VLDL-apo B normally reappears in Sf 0-12 lipoproteins (4). Other investigations, however, have suggested that some apo B in VLDL, or in the Sf 12-20 range, may be catabolized by an altemative pathway (3, 5) . The synthetic rates ofVLDL-apo B and LDLapo B are correlated, but only moderately so (r = +0.57) (7) , which may favor the latter interpretation. Among the possible explanations for these varying reports is the heterogeneity ofthe assumed models for the VLDL-to-LDL cascade, which vary in their complexity and for which there is a dearth of physiological bases.
We have sought an alternative approach, not dependent on model building, to define the kinetics of the metabolism ofapo B-containing lipoproteins in man. By making measurements of apo B mass and radiolabel in different lipoprotein fractions, isolated from samples of arterial and hepatic venous blood following intravenous injection of radioiodinated autologous lipoproteins, the synthesis, interconversion and catabolism of VLDL (Sf 100-400), LDL (Sf 0-12), and intermediate density lipoproteins in the human splanchnic bed have been directly quantified. An analogous approach has been employed by Havel et al. (13) and Boberg et al. (14) for the measurement of splanchnic triglyceride secretion, and more recently by Sniderman et al. (15) to study LDL cholesterol metabolism by the splanchnic viscera.
A further objective of the study concerned the localization of various steps in the VLDL-to-LDL cascade. The paucity of information on regional lipoprotein metabolism in man contrasts with the wealth of animal data obtained, for example, by use of isolated perfused livers (16, 17) , functional hepatectomy (18, 19) , multiple indwelling catheters (20) , and measurement of organ distribution of 1251 following injection of labeled lipoproteins (21 Preparation of radioiodinated autologous lipoproteins. Peripheral venous blood (150 ml) was collected after a 14-h overnight fast, using disodium EDTA (1 mg/ml) as anticoagulant, and plasma was immediately separated by centrifugation at 4°C. When present, chylomicrons (Sf > 400), were removed by aspiration after overlayering plasma with NaCl solution of d = 1.006 g/ml and centrifugation at 20,000 g for 20 min (23) . Subsequently lipoproteins of Sf 100-400, and Sf 0-12 were isolated by sequential preparative ultracentrifugation at 4°C in an MSE Prepspin 50 centrifuge, according to previously described procedures (23, 24) ; an MSE 900 rotor (MSE Scientific Instruments, Sussex, England) was used.
4 vol of plasma were overlayered with 2 vol ofd 1.006 g/ml solution, and centrifuged at 87,000 g for 50 min (24) . The supematant lipoproteins (Sf 100-400) were removed by aspiration, and concentration by recentrifugation under similar conditions. The Assuming a molecular weight of300,000 for total VLDL apolipoprotein (4) and 100,000 for LDL apolipoprotein (2) , a maximum of one iodine atom was incorporated per molecule of protein. Free iodide was partially removed from the preparation by passage through a column of Sephadex G-10 (20 x 0.5 cm). Sterile human serum albumin was added to the eluted lipoprotein (final concentration, 5% wt/vol) to minimize auto-irradiation damage. Residual free iodide was removed by dialysis against 0.15 M NaCl -1 mg/dl Na2EDTA (pH 7.4). The labeled lipoproteins were then made up to 10 ml with 0.15 M NaCl and passed through a 0.45-gm filter (Millipore Corp., Bedford, Mass.). Less than 4% of the radioactivity in the final preparations organic aqueous solutions were made up in pyrogen-free diswas present as free iodide, as determined by precipitation with tilled water, sterilized by autoclaving, and stored at 4°C. Cellu-15% trichloroacetic acid (10 min, 21°C). The percentage of lose nitrate ultracentrifuge tubes were sterilized with 70% radiolabel in the lipid moiety averaged 4.5% in Sf 100-400, isopropanol, and all lipoprotein manipulations were con-4.7% in Sf 12-60, and 3.0% in Sf 0-12 lipoproteins, as deter-ducted, whenever possible, in a laminar flow cabinet. mined by solvent extraction according to Scanu and Edel- Clinical procedures. The studies were carried out in pastein (27) .
tients undergoing routine cardiac catheterization in the course All procedures were carried out using sterile glassware. In-of investigation for suspected coronary heart disease. Elec-tive studies for purely research purposes were not undertaken. The nature of the investigation was discussed with all patients, each of wbom gave informed consent.
Each patient received 50 mg potassium iodide orally each morning from the day of admission until 3 d after catheterization, to minimize thyroidal uptake of radioiodine. Catheterization studies were conducted in the morning after a 14-h overnight fast.
Intravenous reinjection of radioiodinated lipoproteins was performed within 96 h of the initial blood collection. Three different protocols were used: ( On each occasion 5-6 mg of lipoprotein protein was injected. There were no pyrogenic or allergic reactions.
The catheterization procedure involved the standard Seldinger technique (28 (29) . The interval between the start ofthe catheterization and blood sampling did not exceed 30 min. Splanchnic plasma flow measurement. After a bolus injection (15 mg, i.v.), indocyanine green (Cardio Green; Hynson, Westcott and Dunning Inc., Baltimore, Md.) was infused (0.5 mg/min) using a Harvard pump for at least 15 min before blood sampling. The concentrations of dye in arterial and hepatic venous plasma were determined spectrophotometrically at 815 nm, using as standard curve dilutions ofthe dye in plasma and a plasma blank. The Fick principle was applied to calculate the splanchnic plasma flow (SPF) (30) pooled data from all patients there was a significant (P < 0.001) increase in concentration of 14.0±2.1% (mean±SEM) and a significant (P < 0.001) decrease in specific activity of 10.5±2.2% across the splanchnic organs, with no significant arteriovenous difference in apo B radioactivity. These results demonstrate secretion of newly synthesized apo B in Sf 100-400 lipoproteins by splanchnic tissues, with no detectable uptake within the region of Sf 100-400 apo B from arterial blood.
Values for the splanchnic secretion rate of Sf 100-400 apo B ranged from 1.9 to 7.0 mg/kg per h. Results in the hypertriglyceridemic patients (Nos. 3, 8, and 11) were higher than those in the normotriglyceridemic patients (Nos. 2, 4-7, 9, 10, and 12), but this difference failed to achieve statistical significance (6.0±0.78 vs. 4.2±0.51 mg/kg per h; 0.05 < P < 0.10). Patient 1 was excluded from this comparison on account of the apparent residual triglyceride-lowering effect of clofibrate (see Table I ).
Sf lipoproteins. As shown in Table III (Table IV ). In the first seven patients (Nos. [13] [14] [15] [16] [17] [18] [19] , in whom this was quantified following a bolus injection of I251-labeled Sf 12-60, the incorporation of 1251 into hepatic vein Sf 0-12 apo B (expressed as a percentage of the total radioactivity removed from Sf 12-60 apo B) appeared to depend upon the interval between injection and blood sampling, increasing from 22 to 53% as the interval was increased from 2 to 5 h. These results are presented in Fig. 1 Results are given as mean±SEM of 24 measurements. Statistical comparisons of arterial and hepatic venous data were performed by Student's t test: * P < 0.05; t P < 0.01; NS, P > 0.05. The segregation of the patients corresponds to the three protocols used (see Table I ). (Fig. 1) . Sf 0-12 lipoproteins. In no patient was there a statistically significant difference between the arterial and hepatic vein concentrations of Sf 0-12 apo B (Table IV) , although in the pooled data there was a trend for the mean concentrations to be greater in the hepatic vein than in the artery (paired t test: 0.05 < P < 0.10). There was no detectable uptake of131I-apo B by the splanchnic organs when 31I-labeled Sf 0-12 lipoproteins were injected intravenously 5 h before blood sampling (Table IV) The results showed that newly synthesized apo B is nsure constancy of secreted by splanchnic tissues as a component of Sf uposition, and all 100-400 lipoproteins in man. Using similar techniques, Zd state. During the net secretion of triglyceride by human splanchnic viscera has been demonstrated (13, 14) , and VLDL production by the perfused rat liver (17, 35, 36 ) is well documented. No splanchnic uptake of Sf 100-400 apo B could be detected in any of the patients studied, on the basis of either mass or radioactivity measurements. It remains possible, however, that some Sf 100-400 trix glyceride was hydrolyzed by splanchnic tissues without producing a detectable shift of 131I-apo B to Sf < 100 lipoproteins. In contrast to the results obtained for Sf 100-400 lipoproteins, no splanchnic secretion of apo B in Sf lipoproteins could be detected. This finding is compatx ible with the evidence from kinetic studies that it is the VLDL subclasses of greatest flotation rate that are the primary secreted forms, the smaller more dense sub- 16 74 classes being largely catabolic products (3, 4, 37 (14) by measurement of arteryhepatic vein differences in triglyceride concentration under similar experimental conditions. Our secretion rates of apo B exceeded, however, the rates of VLDL apo B synthesis in the fed state (low-fat diets) previously obtained in this and other laboratories by kinetic analysis of plasma apo B specific activity decay curves after intravenous injection of radiolabeled VLDL (3) (4) (5) (6) (7) (8) (9) . This suggests that there may be a diurnal variation in the hepatic production of VLDL apo B in man, perhaps in response to the documented diurnal variation in plasma free fatty acid concentrations (39) . It is also possible that there is some recycling of apo B, derived from extracted Sf > 100 particles, into new Sf 100-400 lipoproteins by the liver.
Another notable aspect of this study was the demonstration that the human splanchnic organs extract Sf lipoproteins from the circulation. The role of the liver in the uptake of VLDL "remnants" (19) and chylomicron remnants (18) in the rat is well documented, but there is no published evidence for a similar process in man. The rates of splanchnic Sf 12-60 apo B extraction in eight normotriglyceridemic patients were lower (P < 0.05) than the rates of Sf 100-400 apo B secretion, suggesting that there was some extrasplanchnic catabolism of VLDL particles not resulting in their conversion to Sf 12-60 lipoproteins. The reason for the discrepancy between this result and the evidence from kinetic studies for the quantitative transfer of apo B from VLDL to Sf 0-20 lipoproteins in normotriglyceridemic individuals (2, 4) is not clear, but may be related to the differing experimental conditions under which the measurements were made.
Our results also indicated that a proportion of the Sf 12-60 lipoproteins extracted by the human splanchnic bed is converted to Sf 0-12 lipoproteins. The percentage transfer of extracted Sf 12-60 radioactivity to hepatic vein Sf 0-12 lipoproteins increased in curvilinear manner with increasing time interval between the injection of radiolabeled and blood sampling, perhaps reflecting the presence of a slowly turning-over intermediate pool in the splanchnic tissues. The greatest conversion rates, observed after continuous intravenous infusion of radiolabel for [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] h, averaged 55%.
Our measurements failed to detect any splanchnic extraction of Sf 0-12 lipoproteins. Evidence obtained from tissue culture (40) and animal experiments (41) suggests that LDL is catabolized partly in the liver and partly in extrahepatic tissues. Although our findings do not support a role of the liver in LDL catabolism, they do not exclude this possibility: artery-hepatic vein differences in radioactivity too small to be demonstrated by the procedure used for isolating Sf 0-12 apo B could nevertheless be physiologically significant.
